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PATH: A catalyst for global 
health
PATH’s mission is 
to improve the 
health of people 
around the world 
by advancing 
technologies, 
strengthening 
systems, and 
encouraging 
healthy behaviors.
Global presence
PATH is working in countries shaded orange.
Area of square indicates staff per office.
PATH’s work in vaccines and 
immunization
RANGE OF ACTIVITIES
• Increasing availability 
of existing vaccines.
• Closing the gap in 
Vaccines & 
Immunization
Other PATH 
Work
uptake of newly 
available vaccines.
• Developing technology 
in support of vaccines 
and immunization.
• Working with partners 
to develop new 
vaccines.
Comprehensive approach 
encompassing research and 
development, advocacy, financing, 
distribution, administration, and uptake.
Vaccine development at PATH
Some vaccines are not available while others are not 
affordable or available in sufficient quantity.
Identify candidates and partner with industry, academia, 
public health organizations, and developing-world 
manufacturers.
WHY
HOW
To accelerate the development of new, lifesaving 
vaccines against selected major disease threats in the 
developing world.
PATH’s key contributions are financial resources, 
technical expertise, and partnership facilitation.
GOAL 
WHAT
PATH’s vaccine development 
projects
• Pneumococcal 
disease
• Diarrheal disease
– Rotavirus
– Enterotoxigenic E. 
coli and Shigella
• Influenza
• Malaria
• Meningococcal 
disease Photo
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Focus on major disease threats
• 2.5 million children 
die from vaccine-
preventable 
diseases each year.
• Pneumonia and 
diarrhea are the two 
leading causes of 
under-five deaths in 
the developing 
world.
Source: WHO estimates of the causes of death in children, Lancet 2005.
Establishing partnerships
• Partners: industry, academia, nongovernmental 
organizations, and government agencies.
• Partnerships direct R&D, manufacturing, and 
distribution strengths toward novel technologies.
• Collaborations must lead to improved 
availability, accessibility, and affordability of 
vaccines.
• PATH negotiates partnerships to ensure global 
access.
Global access
Key components of commercial terms:
• Affordability/pricing
• Manufacturing capacity
• Accessibility
• Quality 
Role of product-development 
partnerships
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Developing world 
risk/return
• Mitigate risk
Potential returns
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Private sector
PDP
• Share costs
Vaccines against pneumonia
Up to 1 million children under age five die each year from pneumococcal 
disease—the number one cause of childhood pneumonia.
1 dot = 1,000 deaths
Source: PneumoADIP, 2008.
Pneumococcal partnerships
中 生 集 团 成 都 生 物 制 品 研 究所
Chengdu Institute of Biological Products, CNBG
Developing vaccines against 
diarrheal diseases
PATH is tackling 
diarrheal disease by 
addressing the most 
common cause of 
severe diarrhea, 
rotavirus, and the two 
leading bacterial 
causes of diarrhea, 
enterotoxigenic E. coli
and Shigella.
Vaccines against rotavirus
More than 500,000 children under five die each year from rotavirus 
infection—the number one cause of childhood diarrhea.
Rotavirus partnerships
Vaccines against bacterial 
diarrhea
• At least one million children under five 
die each year from enterotoxigenic 
Escherichia coli (ETEC) and Shigella, 
combined, the leading bacterial causes 
of diarrhea. 
• Currently, no licensed vaccines against 
ETEC or Shigella are available.
Enteric partnerships
EndoBiologics, Inc.
Vaccines against influenza
• Between 250,000 and 500,000 people die 
each year from seasonal influenza, and the 
most severe pandemic caused up to 50 
million deaths. 
• A gap of nearly 6 billion courses exists 
between current influenza vaccine production 
capacity and what is needed to protect the 
global population in a pandemic.
• Current influenza vaccines are difficult to 
produce quickly and in large quantities.
Influenza partnerships
Institute of Experimental 
Medicine
Building influenza vaccine 
capacity in Vietnam
• Human vaccine development in Vietnam 
against pandemic influenza has been a high 
priority for several years in response to H5N1.
• Strongly supported by the governments of Vietnam, 
the United States, Japan, the WHO, and others.
• Three entities initially engaged in human influenza 
A/H5N1 vaccine development and production.
• Surveillance system to identify prevalence and 
seasonality of influenza.
• Progress towards identifying gaps and establishing 
steps to continue development towards licensure.
IVAC – new influenza facility
~ 25m
A factory of approx. 800 m2 will be built 
including Production division, QC and 
offices
Chicken farm and 
other facilities 
will be nearby
 Building site: Suoi Dau farm (20km far from HQ of IVAC)
CNBG institutes
Slide 
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Conclusions
• Vaccines represent one of the most 
successful and cost-effective public health 
interventions available today.
• Millions of children remain underimmunized 
or unimmunized because of the shortage of 
affordable and available vaccines.
• PATH is working to close the immunization 
gap by partnering to develop new vaccines 
and ensuring access to those vaccines for 
developing-country populations.
For further information
 Maximizing the benefits of 
public-private partnerships
 Availability
 Accessibility
 Affordability
 www.path.org
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